Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 29 Antilipemic Drugs.

Similar presentations


Presentation on theme: "Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 29 Antilipemic Drugs."— Presentation transcript:

1 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 29 Antilipemic Drugs

2 2 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Triglycerides and Cholesterol  Two primary forms of lipids in the blood  Water-insoluble fats that must be bound to apolipoproteins, specialized lipid-carrying proteins  Lipoprotein is the combination of triglyceride or cholesterol with apolipoprotein

3 3 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Lipoproteins  Very-low-density lipoprotein (VLDL)  Produced by the liver  Transports endogenous lipids to the cells  Low-density lipoprotein (LDL)  High-density lipoprotein (HDL)  Responsible for “recycling” of cholesterol  Also known as “good cholesterol”

4 4 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.

5 5 Coronary Heart Disease  The risk of CHD in patients with cholesterol levels of 300 mg/dL is three to four times greater than that in patients with levels less than 200 mg/dL

6 6 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Coronary Heart Disease Positive Risk Factors  Age  Male 45 years or older  Female 55 years or older  Family history of premature CHD  Current cigarette smoker

7 7 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Coronary Heart Disease Positive Risk Factors (cont’d)  Hypertension  BP 140/90 or higher, or on antihypertensive medication  Low HDL levels: less than 40 mg/dL  Diabetes mellitus

8 8 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Coronary Heart Disease Negative (Beneficial) Risk Factor  High HDL (“good” cholesterol): 60 mg/dL or higher

9 9 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Treatment Guidelines  Antilipemic drugs  Drugs used to lower lipid levels  Used as an adjunct to diet therapy  Drug choice based on the specific lipid profile of the patient

10 10 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Treatment Guidelines (cont’d)  All reasonable non-drug means of controlling blood cholesterol levels (e.g., diet, exercise) should be tried for at least 6 months and found to fail before drug therapy is considered

11 11 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Antilipemics  HMG-CoA reductase inhibitors (HMGs, or statins)  Bile acid sequestrants  Niacin (nicotinic acid)  Fibric acid derivatives (fibrates)  Cholesterol absorption inhibitor (Zetia)  Combination drugs (Vytorin)

12 12 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Antilipemics: HMG-CoA Reductase Inhibitors (HMGs, or statins)  Most potent LDL reducers  lovastatin (Mevacor)  pravastatin (Pravachol)  simvastatin (Zocor)  atorvastatin (Lipitor)  fluvastatin (Lescol)

13 13 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. HMG-CoA Reductase Inhibitors: Mechanism of Action  Inhibit HMG-CoA reductase, which is used by the liver to produce cholesterol  Lower the rate of cholesterol production

14 14 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. HMG-CoA Reductase Inhibitors: Indications  First-line drug therapy for hypercholesterolemia  Treatment of types IIa and IIb hyperlipidemias  Reduces LDL levels by 30% to 40%  Increases HDL levels by 2% to 15%  Reduces triglycerides by 10% to 30%

15 15 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. HMG-CoA Reductase Inhibitors: Adverse Effects  Mild, transient GI disturbances  Rash  Headache  Myopathy (muscle pain), possibly leading to the serious condition rhabdomyolysis  Elevations in liver enzymes or liver disease

16 16 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Bile Acid Sequestrants  cholestyramine (Questran)  colestipol hydrochloride (Colestid)  colesevelam (tablet form only)  Also called bile acid–binding resins and ion-exchange resins

17 17 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Bile Acid Sequestrants: Mechanism of Action  Prevent resorption of bile acids from small intestine  Bile acids are necessary for absorption of cholesterol

18 18 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Bile Acid Sequestrants: Indications  Type II hyperlipoproteinemia  Relief of pruritus associated with partial biliary obstruction (cholestyramine)  May be used along with statins

19 19 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Bile Acid Sequestrants: Adverse Effects  Constipation  Heartburn, nausea, belching, bloating  These adverse effects tend to disappear over time

20 20 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Niacin (Nicotinic Acid)  Vitamin B 3  Lipid-lowering properties require much higher doses than when used as a vitamin  Effective, inexpensive, often used in combination with other lipid-lowering drugs

21 21 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Niacin: Mechanism of Action  Thought to increase activity of lipase, which breaks down lipids  Reduces the metabolism or catabolism of cholesterol and triglycerides

22 22 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Niacin: Indications  Effective in lowering triglyceride, total serum cholesterol, and LDL levels  Increases HDL levels  Effective in the treatment of types IIa, IIb, III, IV, and V hyperlipidemias

23 23 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Niacin: Adverse Effects  Flushing (caused by histamine release)  Pruritus  GI distress

24 24 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Fibric Acid Derivatives  Also known as fibrates  gemfibrozil (Lopid)  fenofibrate (Tricor)

25 25 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Fibric Acid Derivatives: Mechanism of Action  Believed to work by activating lipase, which breaks down cholesterol  Also suppress the release of free fatty acid from adipose tissue, inhibit synthesis of triglycerides in the liver, and increase secretion of cholesterol in the bile

26 26 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Fibric Acid Derivatives: Indications  Treatment of types III, IV, and V hyperlipidemias

27 27 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Fibric Acid Derivatives: Drug Effects  Decrease the triglyceride levels  Increase HDL by as much as 25%

28 28 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Fibric Acid Derivatives: Adverse Effects  Abdominal discomfort, diarrhea, nausea  Blurred vision, headache  Increased risk of gallstones  Prolonged prothrombin time  Liver studies may show increased function

29 29 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Cholesterol Absorption Inhibitor  ezetimibe (Zetia)  Inhibits absorption of cholesterol and related sterols from the small intestine  Results in reduced total cholesterol, LDL, and triglyceride levels  Also increases HDL levels  Often combined with a statin drug  Clinical usefulness has been questioned; new trials underway  Currently recommended only when patients have not responded to other therapy

30 30 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Herbal Product: Garlic  Used as an antispasmodic, antihypertensive, antiplatelet, lipid reducer  Adverse effects: dermatitis, vomiting, diarrhea, flatulence, antiplatelet activity  Possible interactions with warfarin, diazepam  May enhance bleeding when taken with NSAIDs

31 31 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Herbal Product: Flax  Both the seed and oil of the plant are used  Uses: atherosclerosis, hypercholesterolemia, GI distress, menopausal symptoms  May cause diarrhea and allergic reactions  Possible interactions: antidiabetic drugs, anticoagulant drugs

32 32 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Herbal Product: Omega-3 Fatty Acids  Fish oil products  Used to reduce cholesterol  May cause rash, belching, allergic reactions  Potential interactions with anticoagulant drugs

33 33 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications  Before beginning therapy, obtain a thorough health and medication history  Assess dietary patterns, exercise level, weight, height, VS, tobacco and alcohol use, family history  Assess for contraindications, conditions that require cautious use, and drug interactions

34 34 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d)  Contraindications include biliary obstruction, liver dysfunction, active liver disease  Obtain baseline liver function studies  Patients on long-term therapy may need supplemental fat-soluble vitamins (A, D, K)  Take with meals to decrease GI upset

35 35 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d)  Counsel patient concerning diet and nutrition on an ongoing basis  Instruct patient on proper procedure for taking the medications  Powder forms must be taken with a liquid, mixed thoroughly but not stirred, and NEVER taken dry

36 36 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d)  Other medications should be taken 1 hour before or 4 to 6 hours after meals to avoid interference with absorption  To minimize adverse effects of niacin, start on low initial dose and gradually increase it, and take with meals

37 37 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d)  Small doses of aspirin or NSAIDs may be taken 30 minutes before niacin to minimize cutaneous flushing  Inform patients that these drugs may take several weeks to show effectiveness

38 38 Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d)  Instruct patients to report persistent GI upset, constipation, abnormal or unusual bleeding, and yellow discoloration of the skin  Monitor for adverse effects, including increased liver enzyme studies  Monitor for therapeutic effects  Reduced cholesterol and triglyceride levels


Download ppt "Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 29 Antilipemic Drugs."

Similar presentations


Ads by Google